期刊文献+

促分裂原活化蛋白激酶激活的蛋白激酶-2全新抑制剂的3D-QSAR研究

3D-QSAR study for novel inhibitors of mitogen activated protein kinase-activated protein kinase 2
下载PDF
导出
摘要 促分裂原活化蛋白激酶激活的蛋白激酶-2(MK-2)可以作为治疗类风湿性关节炎(RA)的靶标,并显示出巨大的潜力,此类酶的抑制剂用于治疗RA具有相当好的疗效,一系列β咔啉衍生物对于MK-2具有高的活性和选择性。通过自组织分子场(SoMFA)分析方法建立了MK-2抑制剂———β咔啉衍生物的三维定量构效关系(3D-QSAR)模型。SoMFA模型的相关系数r2=0.731,交叉验证相关系数q2=0.686,标准偏差s=0.388,Fisher检验值F=63.538。该模型具有很好的稳定性和较为满意的预测能力。 The mitogen-activated protein kinase-activated protein kinase 2 (MK-2) has been received a significant interesting for a potential target to treating RA. A 3D-QSAR model was obtained by using self-organizing molecular field analysis (SoMFA) on a series of β-carboline derivatives with highly potent and selective inhibition for MK-2. The statistical result shows that the square of correlation coefficient (r2), cross-validated square of correlation coefficient (q2), standard error (s) and Fisher check value (F) are 0. 731, 0. 686, 0. 388 and 63. 538 respectively. The model has good stability and satisfied predictive ability.
出处 《大连工业大学学报》 CAS 北大核心 2009年第4期239-243,共5页 Journal of Dalian Polytechnic University
关键词 促分裂原活化蛋白激酶激活的蛋白激酶-2 定量构效关系 量子化学 自组织分子场 mitogen activated protein kinase-activated protein kinase 2 quantitative structure activity relationship quantum chemistry self-organizing molecular field
  • 相关文献

参考文献14

  • 1OSPELT C, GAY S. Antirheumatic drugs and gene signatures [J].Current Opinion in Investigational Drugs, 2007, 8:385-389.
  • 2BRENNAN F M, BROWNE K A, GREEN P A, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy[J]. British Journal of Rheumatology, 1997, 36(6) :643-650.
  • 3BRAUN J, SIEPER J. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin [J].Biodrugs, 2003, 17(3):187-199.
  • 4CHEN Z, GIBSON T B, ROBINSON F, et al. MAP kinases[J]. Chemistry Review, 2001, 101(8):2449-2476.
  • 5PARGELLIS C, REGAN J. Inhibitors of p38 mito gen-activated protein kinase for the treatment of rheu matoid arthritis[J]. Current Opinion in Investigational Drugs, 2003, 4:566-571.
  • 6LEE M R, DOMINGUEZ C. MAP kinase p38 inhihitors: clinical results and an intimate look at their interactions with p38 protein[J].Current Medicinal Chemistry, 2005, 12(25) :2979-2994.
  • 7HEGEN M, GAESTEL M, NICKERSON-NUTTER C L, et al. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis[J].The Journal of Immunology, 2006, 177:1913-1917.
  • 8MEYERS M J, TRUJILLO J I, VERNIER W F, et al, Beta-carboline compounds and analogues thereof and their use as mitoge-activated protein kinase-activated protein kinase-2 inhibitors: US, WO2005009370[P]. 2005-03-02.
  • 9ROBINSON D D, WINN P J, LYNE P D, et al. Self-organizing molecular field analysis: a tool for structure-activity studies[J]. Journal of Medicinal Chemistry, 1999, 42(4):573-583.
  • 10CRAMER III R D, PATTERSON D E, BUNCE J D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins[J].Journal of the American Chemical Society, 1988, 110(18):5959-5967.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部